Neuroendocrine studies in affective disorders. Part 1. Plasma prolactin response to thyrotropin-releasing hormone in affective disorders: effect of ECT.
The plasma prolactin response to thyrotropin-releasing hormone, which is thought to be mediated by central 5-HT mechanisms, has been studied in patients with affective disorders. There was no difference between depressive patients (taken as a whole), bipolar patients undergoing a manic phase and controls in the prolactin response to thyrotropin-releasing hormone. When the depressive patients were divided on a genetic basis into familial pure and sporadic depressive disease it was found that the sporadic patients had an enhanced response. The results do not provide any strong evidence to suggest that central 5-HT mechanisms as measured by the prolactin response to thyrotropin-releasing hormone are abnormal in depressed patients or bipolar patients undergoing a manic phase. Patients after ECT had an increased prolactin response to thyrotropin-releasing hormone which may indicate increased sensitivity of central 5-HT receptors following this treatment.
D001714:Bipolar Disorder / Q000097:blood* / Q000628:therapy; D003866:Depressive Disorder / Q000097:blood* / Q000628:therapy; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D012701:Serotonin / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D012701:Serotonin; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin